Dalbavancin Use at a Health System Network in Compliance with a Standard Plan of Treatment for Infective Endocarditis and Osteomyelitis

Authors

Nicholas Lombardi, St. John Fisher UniversityFollow
Anthoula Kritikos, Arnold & Marie Schwartz College of Pharmacy
Jacky Ye, Arnold & Marie Schwartz College of Pharmacy
Victor Cohen, New York City Health

Document Type

Poster Presentation

Publication Date

12-2024

Department

Pharmacy

Abstract

Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and soft tissue infections caused by gram-positive microorganisms.

Used off-label in the management of infective endocarditis in IV drug users, as well as in osteomyelitis infections.

Extremely long half-life of greater than a week.

Potential cost-effective option for susceptible gram-positive infections and increased patient compliance.

Comments

Poster presented at the ASHP Midyear Clinical Meeting & Exhibition in New Orleans, December 8-12, 2024

Publication Information

Lombardi, Nicholas; Kritikos, Anthoula; Ye, Jacky; and Cohen, Victor, "Dalbavancin Use at a Health System Network in Compliance with a Standard Plan of Treatment for Infective Endocarditis and Osteomyelitis" (2024). Doctoral External Publications. Paper 94.
https://fisherpub.sjf.edu/doctoral_ext_pub/94

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.